KOSDAQBiotech & Pharma153710

Optipharm

₩4,375▼ 2.56%2026-11-18 close
Market Cap
₩64.2B
Turnover
₩5,107,895
Volume
1.2K
Shares out.
14.7M
PER
—
PBR
2.6×
EPS
-₩78
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Optipharm: First Quarterly Profit, Vaccine Test Ahead

Optipharm swung to a Q3 2026 operating profit of KRW 182 million, but annual operating losses ran from 2022 through 2025, and its next inflection point depends on the K-FMD vaccine approval and launch timeline.

  1. 1

    Annual revenue rose three straight years from 2023 to 2025, reaching KRW 22.3 billion in 2025 (up 13.8% year on year), the largest year in the 2022–2025 span.

  2. 2

    The operating loss narrowed from KRW 3.38 billion in 2022 to KRW 2.41 billion in 2025, and the operating margin improved from -21.1% to -10.8%.

  3. 3

    The Q3 2026 operating profit of KRW 182 million compares with an operating loss of KRW 525 million a year earlier, while revenue of KRW 6.47 billion rose 13.9% year on year.

  4. 4

    The net loss attributable to controlling shareholders totaled KRW 1.15 billion over the last four quarters, and Q3 2026 was the only quarter in that span with a profit.

  5. 5

    The K-FMD vaccine entered clinical trials in April 2026, and the company plans to complete approval by year-end and begin sales in 2027; these are company targets not yet reflected in reported results.

02

Business structure

Optipharm is a biotechnology company headquartered in Osong, Chungcheongbuk-do, with business lines in animal diagnostics, veterinary drugs, bacteriophage products and Medipig.

The company's IR materials state that it holds the No. 1 share of the domestic livestock animal diagnostics market (about 60%) and says it accumulates roughly 200,000 disease data records a year from domestic farms.

Veterinary drug sales reached KRW 3.6 billion in Q3 2026, a quarterly record for that segment, and the company said its bacteriophage business also kept improving.

Bacteriophages are described as natural microbe-based feed additives that can replace antibiotics for disease prevention, and the company has produced six product types since starting with a feed additive in 2014. In 2022 it expanded its bacteriophage plant, raising maximum capacity from 3.5 tons to about 12 tons.

Export targets named include Southeast Asia, China and the Middle East, while product certification is being pursued in the United States and Europe. The company attributed 2025 revenue growth to animal diagnostic services, molecular diagnostic kits and bacteriophage products.

On the R&D side, it is developing a nanoparticle-based bivalent foot-and-mouth disease vaccine, in a domestic market that still depends heavily on imports. An Edaily report named a vaccine produced by Argentina's Biogenesis Bago as the leading share holder among vaccines used domestically.

The company says it is shifting its business from veterinary to human medicines, and it has been selected as an execution institution for a research program on a multivalent VLP-based hand, foot and mouth disease vaccine.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩5.7B-₩500M−9.2%
2025Q4₩6B-₩300M−5.4%
2026Q1₩5.4B-₩700M−13.5%
2026Q2₩6.6B-₩200M−3.1%
2026Q3₩6.5B₩200M2.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩16B-₩3.4B-₩2B−21.1%−7.0%42.0%
2023₩17.4B-₩2.6B-₩2.4B−15.1%−9.7%56.2%
2024₩19.6B-₩2.5B-₩2.4B−12.5%−8.6%58.5%
2025₩22.3B-₩2.4B-₩2.5B−10.8%−9.8%60.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On a reported basis, annual revenue rose from KRW 16 billion in 2022 to KRW 17.4 billion in 2023 (up 8.5% year on year), KRW 19.6 billion in 2024 (up 13.0%), and KRW 22.3 billion in 2025 (up 13.8%).

Revenue grew three consecutive years from 2023 through 2025, and 2025 was the largest year in the 2022–2025 span, with the company also announcing a fourth straight year of record revenue since its founding.

Operating losses persisted across the period, at KRW 3.38 billion in 2022, KRW 2.63 billion in 2023, KRW 2.45 billion in 2024 and KRW 2.41 billion in 2025, while the operating margin improved from -21.1% to -10.8%.

The company explained that about KRW 700 million of profit improvement from higher sales in 2025 was offset by a similar level of stock compensation expense.

The net loss attributable to controlling shareholders was KRW 2.04 billion, KRW 2.44 billion, KRW 2.36 billion and KRW 2.5 billion from 2022 to 2025, a loss in each of the four years.

The debt-to-equity ratio climbed from 42.0% in 2022 to 60.5% in 2025, with total equity of KRW 25.4 billion and total liabilities of KRW 15.4 billion at year-end 2025. Operating cash flow was negative in every year, at -KRW 2.43 billion, -KRW 1.72 billion, -KRW 595 million and -KRW 1.55 billion.

Quarterly revenue went from KRW 5.68 billion in Q3 2025 to KRW 5.96 billion, KRW 5.36 billion, KRW 6.59 billion and KRW 6.47 billion in Q3 2026.

Operating results moved from a KRW 525 million loss in Q3 2025, a KRW 321 million loss in Q4, a KRW 723 million loss in Q1 2026 and a KRW 206 million loss in Q2 to a KRW 182 million operating profit in Q3 2026.

The company said the end of stock compensation processing in Q1 2026 should add roughly KRW 200 million per quarter in profit improvement from Q2 onward.

05

Industry analysis

The company puts the domestic FMD vaccine market at about KRW 100 billion and the global market at about KRW 2 trillion. An Edaily report said domestic FMD vaccines depend entirely on imports, with imports reaching KRW 100.3 billion in 2023.

The same report estimated the global FMD vaccine market at around KRW 1 trillion a year, which differs from the company's figure, so market size readings vary by source.

As background for antibiotic-alternative demand, the European Union regulated or banned growth-promoting antibiotics in 2006, Korea in 2011, the United States in 2017 and China in 2020. In bacteriophage products, the United States and Europe are cited as the largest demand markets for high-margin products.

In animal diagnostics, the company claims the No. 1 domestic share and points to its accumulated farm disease data as a differentiator. In FMD vaccines, the leading imported product in the domestic market serves as the practical benchmark, and Optipharm aims to substitute imports with a domestically developed product.

Industry cycle position is hard to measure from the available data, and the company's trajectory will likely depend on vaccine approval timing and export certification. Compared with large listed biopharma companies, Optipharm is a small company whose portfolio centers on animal diagnostics and veterinary drugs.

06

Outlook

The company attributes the Q3 2026 swing to a profit to a structural improvement in which higher sales and better margins arrived together, and it believes the second half of 2026 as a whole can be profitable.

It has said revenue has tended to build toward year-end, which makes the Q4 2026 revenue pattern a useful reference point. Because stock compensation processing ended in Q1 2026, the company expects an additional profit improvement of roughly KRW 200 million per quarter from Q2 onward.

The company stressed that the Q3 2026 profit is sustainable, contrasting it with the Q4 2022 profit, which it said was driven largely by one-off year-end effects. For bacteriophage products, the company aims to obtain high-margin product certification in the United States and Europe during the second half of 2026.

The K-FMD vaccine entered clinical trials in April 2026, with a target of completing approval by year-end and beginning sales in 2027, and the CEO has said results should step up once vaccine sales begin.

On the human medicine side, the company was selected as an execution institution for a multivalent VLP-based hand, foot and mouth disease vaccine R&D program, which forms a second axis of its shift in business structure. These items are company plans and targets rather than numeric guidance. The timing and scale of vaccine revenue in reported results will depend on sales after approval.

07

Valuation

PER
—
PBR
2.6×
ROE
-4.6%
EPS
-₩78
BPS
₩1,681
Dividend per share
₩0

Because the last four quarters were net-loss quarters, the price-to-earnings ratio is not calculated. Multiples from the period before the swing to profit are hard to compare directly with the current earnings base.

The price-to-book ratio sits in a range that carries a premium over net asset value attributable to controlling shareholders. The company pays no dividend, so its dividend yield is below the industry average. Bulls read the premium as partly reflecting a future earnings structure after the vaccine launch.

Bears argue that with operating losses and negative operating cash flow continuing, the reported results do not yet give enough support for a premium over book value. How the market reads the valuation could shift once vaccine approval and early sales data appear. The key questions for the valuation are the durability of profitable quarters and the scale of vaccine revenue.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Quarterly profit turn

The Q3 2026 operating profit of KRW 182 million compares with an operating loss of KRW 525 million in Q3 2025, and net profit attributable to controlling shareholders of KRW 164 million also turned positive in the same quarter.

The company cites higher sales and better margins arriving together as evidence of structural improvement. It also stresses that this is only the second quarterly profit since its 2018 listing.

End of stock compensation drag

The company said the end of stock compensation processing in Q1 2026 should add about KRW 200 million per quarter in profit improvement from Q2 onward. In 2025, a roughly KRW 700 million gain from higher sales was offset by stock compensation, so the expiry of this cost directly affects the earnings structure. Excluding stock compensation, the Q1 2026 operating loss of KRW 723 million was about KRW 600 million.

Vaccine launch option

The K-FMD vaccine entered clinical trials in April 2026, with a target of approval by year-end. The company expects results to take a step up once the vaccine is commercialized from 2027.

The company's own estimates of about KRW 100 billion in the domestic market and about KRW 2 trillion globally are cited as the basis for expansion.

09

Bear factors

Four years of operating losses and cash outflow

Operating losses continued for four consecutive years from 2022 through 2025, and the net loss attributable to controlling shareholders was also a loss in each of those years. Operating cash flow was negative in all four years, at -KRW 1.55 billion in 2025.

Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 1.15 billion, so an accumulated loss structure remains even with a profitable quarter.

Volatility in quarterly results

The Q1 2026 operating loss of KRW 723 million was the largest of the last five quarters, followed by a KRW 206 million loss in Q2 and a KRW 182 million profit in Q3. Quarterly revenue also moved sharply, from KRW 5.36 billion in Q1 2026 to KRW 6.59 billion in Q2. Whether profitable quarters translate into a full-year profit will be visible only in the next periodic report.

Rising debt ratio

The debt-to-equity ratio rose from 42.0% in 2022 to 56.2% in 2023, 58.5% in 2024 and 60.5% in 2025. At year-end 2025, total equity was KRW 25.4 billion and total liabilities were KRW 15.4 billion.

When earnings are not building equity, a larger share of liabilities can be read as a sign of narrowing financial flexibility.

10

Risk factors

Regulatory and approval

The FMD vaccine still faces post-trial product approval, and if the year-end approval target slips, the 2027 launch plan would also move back. Bacteriophage export growth depends on country-by-country product certification, so overseas sales pace is tied to those timelines. Approval and certification outcomes are variables outside the company's direct control.

Financial and cash flow

Operating cash flow was negative from 2022 through 2025, and the debt-to-equity ratio reached 60.5% in 2025. Even with profitable quarters, whether that turns into annual cash generation is a question the next annual report will answer. Rising vaccine-related facility and clinical costs could add to financial strain.

Competition and business mix

The FMD vaccine must compete with the leading imported product in the domestic market and will be compared on price and supply stability after localization.

Because the business spans animal diagnostics, veterinary drugs, bacteriophage products and Medipig, profitability differences across segments can translate into swings in overall results. Human vaccine R&D remains at an early stage.

11

What to watch next

  1. End of 2026

    Whether the K-FMD vaccine receives product approval. The company targets approval by year-end and sales from 2027, so the outcome sets the commercialization timeline.

  2. End of 2026

    Progress on high-margin bacteriophage product certification in the United States and Europe, which the company targets for the second half of 2026.

  3. By end of March 2027

    Filing of the 2026 annual report. The Q4 2026 results will be confirmed in a periodic report for the first time, showing the direction of full-year operating results and operating cash flow.

  4. Mid-May 2027

    The Q1 2027 quarterly report. Compared with the KRW 723 million operating loss in Q1 2026, it will show the size of the profit improvement after stock compensation expired.

  5. During 2027

    Whether commercial sales of the K-FMD vaccine begin and the scale of early revenue. This is the first point at which vaccine revenue would appear in results, showing the actual size of the earnings shift the company has described.

12

Overall view

Optipharm's revenue rose three consecutive years from 2023 and reached KRW 22.3 billion in 2025, while the operating loss narrowed from KRW 3.38 billion in 2022 to KRW 2.41 billion in 2025.

Q3 2026 produced a KRW 182 million operating profit, but the KRW 723 million operating loss in Q1 2026 and the KRW 1.15 billion net loss attributable to controlling shareholders over the last four quarters show how volatile quarterly results remain.

Bullish evidence includes sales growth, the quarterly profit turn, the roughly KRW 200 million per quarter improvement from the end of stock compensation, and the planned K-FMD vaccine launch.

Bearish evidence includes four straight years of operating losses, four years of negative operating cash flow, and a debt-to-equity ratio that rose to 60.5% in 2025. The vaccine still has approval and sales stages ahead, so whether company plans become reported results is the central issue.

On valuation, earnings-based multiples are not calculated, and the price-to-book ratio sits at a premium to net asset value, so how the market prices future businesses such as the vaccine is the main point of interpretation.

The next checkpoints are the year-end 2026 vaccine approval decision, the 2026 annual report, and the Q1 2027 results.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. kr.investing.com
  2. ebn.co.kr
  3. kr.investing.com
  4. etoday.co.kr
  5. liveinfo.kr
  6. m.news.nate.com
  7. news.nate.com
  8. vegannews.co.kr
  9. jbnews.com
  10. pharm.edaily.co.kr
  11. m.news.nate.com
  12. optipharm.co.kr
  13. butler.works
  14. investing.com
  15. news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis